Aradigm (NASDAQ:ARDM) shares saw unusually-high trading volume on Tuesday . Approximately 911,244 shares traded hands during trading, an increase of 173% from the previous session’s volume of 333,383 shares.The stock last traded at $1.91 and had previously closed at $1.58.
ARDM has been the topic of a number of recent analyst reports. Zacks Investment Research cut shares of Aradigm from a “hold” rating to a “sell” rating in a research note on Wednesday, January 17th. Ladenburg Thalmann cut shares of Aradigm from a “buy” rating to a “neutral” rating in a research note on Friday, January 12th. Finally, ValuEngine raised shares of Aradigm from a “sell” rating to a “hold” rating in a research note on Wednesday, January 10th.
The company has a market cap of $28.98, a P/E ratio of -2.38 and a beta of 0.89. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of -1.20.
Aradigm (NASDAQ:ARDM) last issued its quarterly earnings data on Thursday, March 29th. The company reported ($0.28) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.08. The business had revenue of $2.37 million during the quarter. research analysts anticipate that Aradigm will post -1.07 EPS for the current year.
In related news, insider Juergen Kurt Froehlich sold 17,011 shares of the stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $1.53, for a total value of $26,026.83. Following the sale, the insider now directly owns 90,853 shares of the company’s stock, valued at approximately $139,005.09. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 7.30% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Jane Street Group LLC acquired a new stake in Aradigm in the 3rd quarter valued at about $122,000. Eversept Partners LLC acquired a new stake in Aradigm in the 4th quarter valued at about $349,000. Finally, Geode Capital Management LLC acquired a new stake in Aradigm in the 4th quarter valued at about $422,000. 36.88% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This news story was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://ledgergazette.com/2018/04/19/aradigm-ardm-sees-large-volume-increase.html.
Aradigm Company Profile
Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. The company's lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq (ARD-3150) and Lipoquin (ARD-3100) that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis and cystic fibrosis.
Receive News & Ratings for Aradigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aradigm and related companies with MarketBeat.com's FREE daily email newsletter.